ホーム › 転移性癌 › ペンシルベニア › Pittsburgh
Pittsburgh、PAにおける転移性癌の臨床試験
Pittsburghとその周辺地域（約30マイル以内）の拠点で、転移性癌に関する31件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- UPMC-Magee Womens Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- 他3件
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- University of Pittsburgh Medical Center, Pittsburgh
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
被験者募集中第2/3相
- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- University of Pittsburgh Medical Center, Pittsburgh
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
被験者募集中第3相
- AHN Allegheny General Hospital, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Allegheny Health Network, Pittsburgh
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
被験者募集中第1/2相
- UPMC Hillman Cancer Center ( Site 0014), Pittsburgh
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Clinical Study Site, Pittsburgh
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
被験者募集中第1相
- Allegheny General Hospital, Pittsburgh
- University of Pittsburgh Medical Center, Pittsburgh
FOG-001 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
被験者募集中第1/2相
- UPMC Hillman Cancer Center, Pittsburgh
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
被験者募集中第3相
- Research Site, Pittsburgh
- Research Site, Pittsburgh
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
被験者募集中第1相
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
被験者募集中第3相
- AHN Cancer Center, Pittsburgh
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
被験者募集中第1相
- University of Pittsburg Medical Center (UPCM), Pittsburgh
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
被験者募集中第2/3相
- University of Pittsburgh Medical Center(UPMC)-Hillman Cancer Center, Pittsburgh
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
被験者募集中第1/2相
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
被験者募集中第2/3相
- UPMC Hillman Cancer Center, Pittsburgh
Window of Opportunity in Preserving Laryngeal Function Trial
被験者募集中第2相
- UPMC Hillman Cancer, Pittsburgh
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
被験者募集中第3相
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
被験者募集中第2/3相
- UPMC Hillman Cancer Center, Pittsburgh
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
被験者募集中第1相
- Hillman Cancer Center, Pittsburgh
Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)
被験者募集中第2相
- Allegheny Health Network West Penn Hospital, Pittsburgh
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
被験者募集中第3相
- University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
被験者募集中第1/2相
- University of Pittsburgh, Pittsburgh
他の都市における転移性癌の試験
- Houston, TX104件の研究
- New York City, NY93件の研究
- Nashville, TN70件の研究
- Boston, MA63件の研究
- Los Angeles, CA57件の研究
- St. Louis, MO54件の研究
- Arlington, VA53件の研究
- Philadelphia, PA46件の研究
- Chicago, IL45件の研究
- San Antonio, TX44件の研究
- Washington, DC43件の研究
- Dallas, TX42件の研究
Pittsburghにおける他の研究
- 非小細胞肺癌48件の研究
- がん（全種類）41件の研究
- 乳がん39件の研究
- 大腸癌32件の研究
- 悪性黒色腫31件の研究
- 卵巣がん30件の研究
- 子宮内膜がん23件の研究
- 前立腺がん23件の研究
- 肺がん23件の研究
- 頭頸部扁平上皮癌22件の研究
- 脳卒中22件の研究
- うつ病22件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。